menu search

OGN / Is There Anything Organic Or Interesting About Organon?

Is There Anything Organic Or Interesting About Organon?
Organon is a business I own - but only due to being awarded a significant number of shares, some of which I actually sold early on. I kept a stake. In this article, I'm going to follow a subscriber request and dive into what Organon might do for its shareholders, if you did not sell, or may be interested. Read More
Posted: Feb 7 2023, 04:01
Author Name: Seeking Alpha
Views: 110534

OGN News  

Organon & Co (OGN) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 2, 2023

Organon & Co (OGN) Q3 2023 Earnings Call Transcript

Organon & Co (NYSE:OGN ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO M more_horizontal

Organon: The Federal Reserve Black Swan (Rating Upgrade)

By Seeking Alpha
October 4, 2023

Organon: The Federal Reserve Black Swan (Rating Upgrade)

The stock of junk-rated Organon & Co. has lost more than 40% since my first article, largely due to interest rates continuing to rise. I take a close more_horizontal

6% Yield And Significantly Undervalued: A Closer Look At Organon

By Seeking Alpha
September 10, 2023

6% Yield And Significantly Undervalued: A Closer Look At Organon

Organon & Co. stock is down 30% year-to-date and 40% below its 52-week highs. OGN offers a dividend yield of 5.8%, making it an attractive option for more_horizontal

Organon & Co (OGN) Q2 2023 Earnings Call Transcript

By Seeking Alpha
August 8, 2023

Organon & Co (OGN) Q2 2023 Earnings Call Transcript

Organon & Co (NYSE:OGN ) Q2 2023 Earnings Conference Call August 8, 2023 8:30 AM ET Company Participants Jennifer Halchak - VP, IR Kevin Ali - CEO Mat more_horizontal

Organon results beat estimates on demand for women heath products, biosimilars

By Reuters
August 8, 2023

Organon results beat estimates on demand for women heath products, biosimilars

Organon & Co reported better-than-expected second-quarter results on Tuesday, helped by strong demand for its women's heath products and biosimilar dr more_horizontal

Final Trades: SLB, Organon, IQVIA & more

By CNBC Television
July 14, 2023

Final Trades: SLB, Organon, IQVIA & more

The "Halftime Report" traders give their top picks to watch for the second half. more_horizontal

Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.

By Market Watch
July 5, 2023

Organon and Samsung Bioepis launch Humira biosimilar Hadlima in the U.S.

Organon & Co. OGN, -1.15% and partner Samsung Bioepis Co. Ltd. said Wednesday they have launched their Humira biosimilar Hadlima in the U.S. The move more_horizontal

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount

By Reuters
July 1, 2023

Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount

Drugmaker partners Organon and Samsung Bioepis said on Saturday that they had launched a far cheaper copycat version of AbbVie's blockbuster arthritis more_horizontal


Search within

Pages Search Results: